319 related articles for article (PubMed ID: 29427151)
1. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
[TBL] [Abstract][Full Text] [Related]
2. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
4. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
[TBL] [Abstract][Full Text] [Related]
6. Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours.
Łastowska M; Jurkiewicz E; Trubicka J; Daszkiewicz P; Drogosiewicz M; Malczyk K; Grajkowska W; Matyja E; Cukrowska B; Pronicki M; Perek-Polnik M; Perek D; Dembowska-Bagińska B
J Neurooncol; 2015 May; 123(1):65-73. PubMed ID: 25862008
[TBL] [Abstract][Full Text] [Related]
7. ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Tarasińska M; Perek-Polnik M; Krętowski A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Matyja E
Am J Surg Pathol; 2017 Jun; 41(6):781-787. PubMed ID: 28338501
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
[TBL] [Abstract][Full Text] [Related]
9. Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).
Gajjar A; Robinson GW; Smith KS; Lin T; Merchant TE; Chintagumpala M; Mahajan A; Su J; Bouffet E; Bartels U; Schechter T; Hassall T; Robertson T; Nicholls W; Gururangan S; Schroeder K; Sullivan M; Wheeler G; Hansford JR; Kellie SJ; McCowage G; Cohn R; Fisher MJ; Krasin MJ; Stewart CF; Broniscer A; Buchhalter I; Tatevossian RG; Orr BA; Neale G; Klimo P; Boop F; Srinivasan A; Pfister SM; Gilbertson RJ; Onar-Thomas A; Ellison DW; Northcott PA
J Clin Oncol; 2021 Mar; 39(7):822-835. PubMed ID: 33405951
[TBL] [Abstract][Full Text] [Related]
10. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
11. Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy.
Blüml S; Margol AS; Sposto R; Kennedy RJ; Robison NJ; Vali M; Hung LT; Muthugounder S; Finlay JL; Erdreich-Epstein A; Gilles FH; Judkins AR; Krieger MD; Dhall G; Nelson MD; Asgharzadeh S
Neuro Oncol; 2016 Jan; 18(1):126-31. PubMed ID: 26254476
[TBL] [Abstract][Full Text] [Related]
12. Histologic Correlates of Molecular Group 4 Pediatric Medulloblastoma: A Retrospective Canadian Review.
Triscott J; Yip S; Johnston D; Michaud J; Rassekh SR; Hukin J; Dunn S; Dunham C
Pediatr Dev Pathol; 2021; 24(4):309-317. PubMed ID: 33749384
[TBL] [Abstract][Full Text] [Related]
13. Paired box gene 8 (PAX8) expression is associated with sonic hedgehog (SHH)/wingless int (WNT) subtypes, desmoplastic histology and patient survival in human medulloblastomas.
Harter PN; Baumgarten P; Zinke J; Schilling K; Baader S; Hartmetz AK; Schittenhelm J; Beschorner R; Liebner S; Schulte D; Plate KH; Gutwein P; Korshunov A; Pfister SM; Jones DT; Doberstein K; Mittelbronn M
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):165-79. PubMed ID: 25287489
[TBL] [Abstract][Full Text] [Related]
14. A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.
Gómez S; Garrido-Garcia A; Garcia-Gerique L; Lemos I; Suñol M; de Torres C; Kulis M; Pérez-Jaume S; Carcaboso ÁM; Luu B; Kieran MW; Jabado N; Kozlenkov A; Dracheva S; Ramaswamy V; Hovestadt V; Johann P; Jones DTW; Pfister SM; Morales La Madrid A; Cruz O; Taylor MD; Martin-Subero JI; Mora J; Lavarino C
Clin Cancer Res; 2018 Mar; 24(6):1355-1363. PubMed ID: 29351917
[No Abstract] [Full Text] [Related]
15. Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis.
Zhao F; Zhang J; Li P; Zhou Q; Zhang S; Zhao C; Wang B; Yang Z; Li C; Liu P
J Neurooncol; 2018 Sep; 139(2):333-340. PubMed ID: 29687281
[TBL] [Abstract][Full Text] [Related]
16. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
von Bueren AO; Kortmann RD; von Hoff K; Friedrich C; Mynarek M; Müller K; Goschzik T; Zur Mühlen A; Gerber N; Warmuth-Metz M; Soerensen N; Deinlein F; Benesch M; Zwiener I; Kwiecien R; Faldum A; Bode U; Fleischhack G; Hovestadt V; Kool M; Jones D; Northcott P; Kuehl J; Pfister S; Pietsch T; Rutkowski S
J Clin Oncol; 2016 Dec; 34(34):4151-4160. PubMed ID: 27863192
[TBL] [Abstract][Full Text] [Related]
18. [Molecular subgrouping and characterization analysis of medulloblastomas in a cohort of Japanese patients].
Wataya T; Hamasaki M; Taylor MD
No Shinkei Geka; 2015 Feb; 43(2):117-25. PubMed ID: 25672552
[TBL] [Abstract][Full Text] [Related]
19. Texture Analysis of T1-Weighted Contrast-Enhanced Magnetic Resonance Imaging Potentially Predicts Outcomes of Patients with Non-Wingless-Type/Non-Sonic Hedgehog Medulloblastoma.
Li J; Chen C; Fu R; Zhang Y; Fan Y; Xu J; Cen Y
World Neurosurg; 2020 May; 137():e27-e33. PubMed ID: 31589984
[TBL] [Abstract][Full Text] [Related]
20. Rapid diagnosis of medulloblastoma molecular subgroups.
Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
